Innate Pharma S.A.

What they do

Innate Pharma focuses on developing natural killer (NK) cell-based immunotherapies and antibody-drug conjugates (ADCs) for cancer. Its lead programs include monalizumab (anti-NKG2A) partnered with AstraZeneca, and IPH6101 (SAR443579) an anti-CLL1 ADC partnered with Sanofi. The company also has early-stage research collaborations with Takeda. Operations are primarily funded through partner milestone payments and equity offerings.

Revenue drivers

• AstraZeneca partnerships — Collaboration on monalizumab and IPH5201, including licensing fees, milestone payments, and royalties. Financial details are not specified in the provided excerpts.
• Sanofi NK cell engages and ADC agreement — Agreements cover NK cell engagers and IPH6101 (SAR443579), with payments including option fees and potential milestones. Specific amounts are not disclosed.
• Takeda ADC research collaboration — Research agreement on antibody-drug conjugates initiated in 2024, with unspecified financial terms.

Recent performance

The annual report for fiscal year 2025 was filed on April 1, 2026. The company reported cash, cash equivalents, and financial assets denominated in USD at year-end 2025, but exact figures are not provided in the excerpts. In 2024 and 2025, the company engaged in equity offerings, including a private placement to Sanofi in April 2025. Operating results for 2025 are not detailed in the provided source material.

Strategy

Innate Pharma focuses on advancing its proprietary pipeline while leveraging partnerships with major pharma companies. Key collaborations include multiple agreements with AstraZeneca (monalizumab, IPH5201) and Sanofi (NK cell engagers, IPH6101). The company also in-licensed PH5401 (anti-C5aR) from Novo Nordisk. Recent strategy includes raising capital through equity offerings, such as an investment from Sanofi in April 2025, to fund research and development.

Risks

• Dependence on partnerships — A significant portion of development and funding relies on partners like AstraZeneca and Sanofi, and any change in their priorities could impact progress.
• Clinical and regulatory uncertainty — As a clinical-stage company, its product candidates may fail in trials or face regulatory hurdles, affecting value.
• Financial risk — The company has ongoing cash needs; if equity markets or partner payments are insufficient, it may require additional dilutive financing.
• Foreign exchange exposure — Holding cash in USD while operating in EUR exposes the company to currency fluctuations, which could affect financial results.

Outlook

Management's outlook is not directly stated in the provided excerpts. However, the company's actions indicate continued focus on advancing its pipeline through partnerships and collaborations. The recent investment by Sanofi suggests ongoing support for key programs. Future development and financial results will depend on trial outcomes and partner milestones.